Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Australia: ResApp plans new cough trial

Shares in ResApp Health jumped more than 28% earlier this week after the investigators of the group’s clinical trial confirmed that their study was not an accurate or reliable evaluation of ResApp’s algorithms. The release of the initial trials caused shares in the Perth-based digital healthcare operator that focuses on respiratory diseases to crash 77% after they showed significant problems with its main product.

“Having completed a review with all relevant parties it is clear that the first US study was not a reliable evaluation of ResApp’s algorithms and that the top line results do not reflect the actual performance of ResApp’s technology,” said ResApp CEO and managing director Tony Keating.

ResApp’s main product is a cough-based diagnostic test that works with a smartphone to analyse the sound of a patient’s cough and to diagnose any underlying conditions.

In that trial, two main problems were found. First, that contrary to instructions and training, a high number of patients were treated before clinical research staff recorded their cough sounds. And second, a high number of recordings were found to contain a second person’s cough sounds or an unacceptable amount of background noise and interference.

ResApp  plans to restart the study  this winter in the US.

To improve the data gathering element of the study, ResApp will be present onsite conducting clinical study team training, reviewing enrolment procedures and verifying data to help ensure that high-quality cough sounds are collected as early as possible during the patient’s hospital visit and prior to any treatment known to affect cough analysis. Every cough sound collected will be quality checked within days of its recording to ensure that all of the data used to subsequently analyse the performance of the algorithm is uncorrupted and high fidelity. An improved audio recording smartphone application incorporating built-in checklists, automated background noise estimation and additional visual aids will be deployed further to support the data collection teams and eliminate inappropriate collection of cough data with background noise contamination.

ResApp’s algorithms have also been modified to reduce the impact of the low frequency electronic interference found in nearly 15% of the previous study recordings.

ResApp plans to broaden its paediatric clinical strategy by reconfiguring its Australian study to support European and Australian regulatory filings directly. Since earlier this year, the Australian paediatric study at Joondalup Hospital has been recruiting patients for double-blind prospective analysis with 230 patients recruited to date. To support regulatory submissions, a team of clinicians will perform adjudication and Curtin University health researchers will provide independent statistical analysis.

ResApp shares closed on Monday at A$0.09 (US$0.07).

Posted on: 06/09/2017 UTC+08:00


News

A 29-year-old doctor in Wuhan has become the latest victim of the coronavirus as worldwide panic about the pandemic continues to grow, The Guardian has reported.
Healthcare company Oue Lippo Healthcare has announced a profit of S$3.2 million ($2.3 million) for 2019, which compares to a loss of S$9.3 million reported for 2018.
Beijing-based China Jo-Jo Drugstores has reported a small net profit of $456,000 for the third quarter of its 2020 fiscal year, ending 31 December 2019, compared to a net loss of $2.2 million reported for Q3 2109.
The head of a leading hospital in Wuhan, the epicentre of a coronavirus outbreak, has died of the disease, according to China’s state television.
New Delhi-based Hempstreet, a research-to-retail healthcare start-up that focuses on cannabis uses in Ayurvedic medicine, has raised $1 million in pre-series A funding.
Sydney-based George Clinical, a global clinical research organisation, has appointed James as chief executive, replacing Glenn Kerkhof who becomes chairman.
Thomson Medical Group’s pre-tax profit for 2019 was $14.7 million, down 33% from the $22 million reported for 2018.
Ping An Healthcare and Technology Company has announced a 2019 loss of ¥746.7 million ($107.1 million), which compares to a net loss of ¥913.1 million announced for 2018.



Analysis

L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.


Podcasts

HealthInvestor Asia twitter feed